Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151(2):187-194 | DOI: 10.5507/bp.2007.033

RETINOIDS, REXINOIDS AND THEIR COGNATE NUCLEAR RECEPTORS: CHARACTER AND THEIR ROLE IN CHEMOPREVENTION OF SELECTED MALIGNANT DISEASES

Julius Brtko
Institute of Experimental Endocrinology, Slovak Academy of Sciences, Laboratory of Molecular Endocrinology, Bratislava, Slovak Republic

Background: Retinoids, rexinoids and their biologically active derivatives are involved in a complex arrangement of physiological and developmental responses in many tissues of higher vertebrates. Both retinoids and rexinoids are either natural or synthetic compounds related to retinoic acids that act through interaction with two basic types of nuclear receptors belonging to the nuclear receptor superfamily: All-trans retinoic acid receptors (RARα, RARβ, and RARγ) and retinoid X receptors (RXRα, RXRβ and RXRγ) as retinoid-inducible transcription factors.

Aim: Summarization of selected effects of biologically active natural or synthetic retinoids and rexinoids and their exploitation in chemoprevention of various types of cancer.

Results: Retinoid receptors play a role as ligand-activated, DNA-binding, trans-acting, transcription-modulating proteins involved in a general molecular mechanism responsible for transcriptional responses in target genes. They exert both beneficial and detrimental activity; they have tumour-suppressive activity but on the other hand they are teratogenic. A number of nuclear receptor selective retinoids and rexinoids, have been successfully tested using a variety of cell lines or animal models. Retinoids inhibit carcinogenesis, suppress premalignant epithelial lesions and tumour growth and invasion in a variety of tissues. Concusions: Natural and synthetic retinoids exert important biological effects due to their antiproliferative and apoptosis-inducing effects. They are also known to cause redifferentiation or to prevent further dedifferentiation of various tumour tissues.

Keywords: Retinoids, Nuclear receptors, Ligand inducible transcription factors, Cancer chemoprevention, Tumour, Regulation of transcription, Gene expression

Received: September 25, 2007; Accepted: October 8, 2007; Published: December 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brtko, J. (2007). RETINOIDS, REXINOIDS AND THEIR COGNATE NUCLEAR RECEPTORS: CHARACTER AND THEIR ROLE IN CHEMOPREVENTION OF SELECTED MALIGNANT DISEASES. Biomedical papers, 151(2), 187-194. doi: 10.5507/bp.2007.033
Download citation

References

  1. DeLuca LM. Retinoids and their receptors in diff erentiation, embryogenesis and neoplasia. FASEB J 1991; 5:292433. Go to original source...
  2. Lotan R. Retinoids and apoptosis: Implication for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87:16557. Go to original source... Go to PubMed...
  3. Sun S-Y, Lotan R. Retinoids as chemopreventive and therapeutic agents. Drugs Fut 1998; 23:62134. Go to original source...
  4. Hinds TS, West WL, Knight EM. Carotenoids and retinoids: a review of research, clinical, and public health application. J Clin Pharmacol 1997; 37:5518. Go to original source...
  5. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10:9405. Go to original source...
  6. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006; 58:685704. Go to original source... Go to PubMed...
  7. Nagpal S, Friant S, Nakshatri H, Chambon P. RARs and RXRs: Evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 1993; 12:2349 60. Go to original source...
  8. Mader S, Leroy P, Chen JY, Chambon P. Multiple parameters control the selectivity of nuclear receptors for their response elements. J Biol Chem 1993; 268:591600. Go to original source...
  9. Durand B, Saunders M, Gaudon C, Roy B, Losson R, Chambon P. Activation function (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutively activating domain and infl uence of the nature of the response element. EMBO J 1994; 13:537082. Go to original source...
  10. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell 1995; 85:8359. Go to original source... Go to PubMed...
  11. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81:1269304. Go to original source... Go to PubMed...
  12. Bain DL, Heneghan AF, Connaghan-Jones KD, Miura MT. Nuclear receptor structure: implications for function. Ann Rev Physiol 2006; 69:20120. Go to original source... Go to PubMed...
  13. Sun S-Y, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41:4155. Go to original source... Go to PubMed...
  14. Minucci S, Leid M, Toyama R, Saint-Jeannet JP, Peterson VJ, Horn V, Ishmael JE, Bhattacharyya N, Dey A, Dawid IB, Ozato K. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid dependent gene expression. Mol Cell Biol 1997; 17:644655. Go to original source...
  15. Crowe DL. Receptor selective synthetic retinoids as potential cancer chemotherapy agents. Curr Cancer Drug Targets 2002; 2:7786. Go to original source... Go to PubMed...
  16. Freedman, LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999; 97:58. Go to original source... Go to PubMed...
  17. Privalsky ML. Regulation of SMRT and N-CoR corepressor function. Curr Top Microbiol Immunol 2001; 254:11736. Go to original source... Go to PubMed...
  18. Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005; 6:54254. Go to original source... Go to PubMed...
  19. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:40710. Go to original source... Go to PubMed...
  20. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83:84150. Go to original source... Go to PubMed...
  21. Willy PJ, Mangelsdorf DJ. Nuclear orphan receptors: the search for novel ligands and signaling pathways. Horm Signal 1998; 1:307 358. Go to original source...
  22. Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raff elsberger W, Gronemeyer H, Lanotte M. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J 1999; 18:70117018. Go to original source... Go to PubMed...
  23. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21:525530. Go to original source... Go to PubMed...
  24. Germain P, Iyer J, Zechel C, Gronemeyer H. Coregulator recruitment and the mechanism of retinoic acid synergy. Nature 2002; 415:18792. Go to original source... Go to PubMed...
  25. Zhang J, Zamir I, Lazar MA. Diff erential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression. Mol Cell Biol 1997; 17:6887 97. Go to original source... Go to PubMed...
  26. Li E, Sucov HM, Lee KF, Evans RM, Jaenisch R. Normal development and growth of mice carrying a targeted disruption of the alpha 1 retinoic acid receptor gene. Proc Natl Acad Sci USA 1993; 90:15904. Go to original source...
  27. Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci USA 1993; 90:72259. Go to original source...
  28. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006; 58:71225. Go to original source... Go to PubMed...
  29. Chapellier B, Mark M, Messaddeq N, Calleja C, Warot X, Brocard J, Gerard C, Li M, Metzger D, Ghyselinck NB, Chambon P. Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled. EMBO J 2002; 21:340213. Go to original source... Go to PubMed...
  30. Kastner P, Grondona JM, Mark M, Gansmuller A, LeMeur M, Decimo D, Vonsech JL, Dolle P, Chambon P. Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 1994; 78:9871003. Go to original source... Go to PubMed...
  31. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, Evans RM. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev 1994; 8:1007 18. Go to original source... Go to PubMed...
  32. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006; 58:78297. Go to original source... Go to PubMed...
  33. Kastner P, Mark M, Leid M, Gansmuler A, Chin W, Grondona JM, Decimo D, Krezel W, Dierich A, Chambon P. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev 1996; 10:8092. Go to original source... Go to PubMed...
  34. Mascrez B, Ghyselinck NB, Watanabe M, Annicotte JS, Chambon P, Auswerx J, Mark M. Ligand-dependent contribution of RXR beta to cholesterol homeostasis in Sertoli cells. EMBO Rep 2004; 5:28590. Go to original source... Go to PubMed...
  35. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH Krezel W, Chambon P, Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-defi cient mouse. J Clin Invest 2000; 106:739. Go to original source... Go to PubMed...
  36. Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: Established and novel directed therapies for cancer and chemoprevention. Curr Pharm Design 2003; 9:206777. Go to original source... Go to PubMed...
  37. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet 1999; 15:17984. Go to original source... Go to PubMed...
  38. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:17789. Go to original source... Go to PubMed...
  39. Zhang J-W, Gu J, Wang Z-Y, Chen S-J, Chen Z. Mechanisms of alltrans retinoic acid-induced diff erentiation of acute promyelocytic leukemia cells. J Biosci 2000; 25:27584. Go to original source... Go to PubMed...
  40. Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ. Retinoic acid regulatory pathways, chromosomal translocations and acute promyelocytic leukemia. Genes Chromosomes Cancer 1996; 15:14756. Go to original source... Go to PubMed...
  41. Melnick A, Licht JD. Deconstructing a disease: RAR alpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167215. Go to original source...
  42. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 1999; 18:527892. Go to original source... Go to PubMed...
  43. Altucci L, Gronemeyer H. The promise of retinoids to fi ght against cancer. Nat Rev Cancer 2001; 1:18193. Go to original source... Go to PubMed...
  44. Fenaux P, Wang ZZ, Degos L. Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 2007; 313:10128. Go to original source... Go to PubMed...
  45. Mehta RG. Experimental basis for the prevention of breast cancer. Eur J Cancer 2000; 36:127582. Go to original source... Go to PubMed...
  46. Fontana JA, Mezu AB, Copper BN, Miranda D. Retinoid modulation of estradiol-stimulated growth and of protein synthesis and secretion in human breast carcinoma cells. Cancer Res 1990; 50:19972002.
  47. Macejova D, Dvorcakova M, Weiss R, Scheiblhofer S, Mostbock S, Liska J, Szabova L, Zorad S, Thalhamer J, Brtko J. Reduction of 1-methyl-1-nitrosourea-insuced mammary gland carcinoma by in vivo application of immunostimulatory CpG motifs in Sprague- Dawley rats. Gen Physiol Biophys 2001; 20:4458.
  48. Brtko J. Role of retinoids and their cognate nuclear receptors in breast cancer chemoprevention. Cent Eur J Public Health 2007; 15:36. Go to original source...
  49. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocrine-Related Cancer 2006; 13:5168. Go to original source... Go to PubMed...
  50. Macejova D, Baranova M, Liska J, Brtko J. Expression of nuclear hormone receptors, their coregulators and type I iodothyronine 5-deiodinase gene in mammary tissue of nonlactating and postlactating rats. Life Sci 2005; 77:258493. Go to original source... Go to PubMed...
  51. Zhang X-K, Liu Y, Lee MO. Retinoid receptors in lung cancer and breast cancer. Mutation Research 1996; 350:26777. Go to original source... Go to PubMed...
  52. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56:556670.
  53. Moon RC, Constantinou AI. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res Treat 1997; 46:1819. Go to original source... Go to PubMed...
  54. Zujewski J, Pai L, Wakefi eld L, Giusti R, Dorr FA, Flanders C, Caruso R, Kaiser M, Goodman L, Merino M, Gossard M, Noone MA, Denicoff A, Venzon D, Cowan KH, O'Shaughnessy JA. Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat 1999; 57:27783. Go to original source... Go to PubMed...
  55. Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 2001; 3:99103. Go to original source... Go to PubMed...
  56. Zhang X-K. Vitamin A and apoptosis in prostate cancer. Endo Related Cancer 2002; 9:87102. Go to original source... Go to PubMed...
  57. Haugen BR. Rediff erentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4:17580. Go to original source... Go to PubMed...
  58. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids a review. Exp Clin Endocrinol Diabetes 2001; 109:414. Go to original source... Go to PubMed...
  59. Schmutzler C, Köhrle J. Retinoic acid rediff erentiation therapy for thyroid cancer. Thyroid 2000; 10:393406. Go to original source... Go to PubMed...
  60. Van Herle AJ, Agatep ML, Padua DN 3rd, Van Herle HML, Juillard, GJF. Eff ects of 13-cis retinoic acid on growth and diff erentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990; 71:75563. Go to original source... Go to PubMed...
  61. Schreck R, Schneiders F, Schmutzler C, Köhrle J. Retinoids stimulate type-I iodothyronine 5-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994; 79:7918. Go to original source... Go to PubMed...
  62. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997; 240:8328. Go to original source... Go to PubMed...
  63. Schmutzler C, Schmitt TL, Glaser F, Loos U, Köhrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 2002; 189:14555. Go to original source... Go to PubMed...
  64. Schmutzler C, Köhrle J. Innovative strategies for treatment of thyroid cancer. Eur J Endocrinol 2000; 143:1524. Go to original source... Go to PubMed...
  65. Schmutzler C, Brtko J, Bienert K, Köhrle J. Eff ect of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 1996; 104(Suppl. 4):169. Go to original source... Go to PubMed...
  66. Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D, Goretzki PE, Köhrle J. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998; 76:36876. Go to original source... Go to PubMed...
  67. Boerner AR, Petrich T, Weckesser E, Fricke H, Hofmann M, Otto D, Weckesser M, Langen KJ, Knapp WH. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur J Nucl Med 2002; 29:2316. Go to original source...